Mr. Goldberger has more than 25 years of experience in the medical technology and device industry. Prior to joining Bacterin, Dan was the CEO of Sound Surgical Technologies from April 2007 through its merger with Solta Medical (Nasdaq SLTM) in February 2013. During his career, he has held several executive leadership positions within the medical device industry, as the CEO and Director of Xcorporeal Inc. and President of Medical Group of OSI Systems. He holds a BS in Mechanical Engineering from the Massachusetts Institute of Technology and an MS in Mechanical Engineering from Stanford University. Dan is a named inventor on more than 60 U.S. patents.
Mr. Gandolfo has 26 years of experience as chief financial officer of rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising including 4 public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career.
Mr. Di Silvio has over 30 years of experience serving in executive management positions in the medical industry, overseeing sales and marketing efforts in the management of medical sales operations. Prior to joining Bacterin, Mr. Di Silvio served as Senior Vice President and General Manager of the Americas region for Lumenis since January 2012, and prior to that role, as Senior Vice President and General Manager, Lumenis North America Region. Mr. Di Silvio previously served as President and Chief Executive Officer of Pyng Medical Inc.; as Vice President Global Sales and Marketing of Safe Life; as Vice President of US Field Operations Physio-Control Division of Medtronic, Inc.; and as Vice President, US Field Operations of Coherent Medical Group ("CMG"). Mr. Di Silvio currently serves as a member of the board of directors of Pyng Medical Corp. He holds a bachelor's degree in economics and organic chemistry and a master's degree in biochemistry from the University of Connecticut, and he also completed three years at the University of Rome School of Medicine, Italy. As President of the Company, Mr. Di Silvio will be responsible for management of sales, marketing and business development.
Mr. Holmes has over 25 years of experience in the medical device, biologics, and diagnostic industries. He previously served as Operations Executive for American Qualex, HYCOR Biomedical and Stratagene, and as Executive Vice President and COO of Big Spring Water Company. Since joining Bacterin International, Inc. in 2003, Mr. Holmes has assumed responsibilities for all aspects of medical device and biologic product design and development, process scale-up, and production. He is also responsible for the establishment and maintenance of a quality system that is compliant with FDA CFR Title 21 Parts 820 and 1271, AATB, and ISO 13485. Mr. Holmes has worked with numerous regulatory agencies at the federal, state, and local level and oversees Bacterin’s regulatory compliance and environmental health and safety programs. He is the Management with Executive Responsibility for Bacterin’s operations and he oversees production, facility management, engineering and information technology (IT) to produce Bacterin’s medical devices and biologic products, while accommodating business growth. He directs the design, purchase, validation and implementation of capital assets and facility expansions for the company, and is responsible for strategic planning as well as the development and administration of division-level budgets. Currently, Mr. Holmes serves as the Tissue Bank Director and on Bacterin’s Medical Advisory Committee, as a member of Montana State University’s Employer Advisory Board, and as a Scientific Advisory Board Member for Montana Molecular in Bozeman, Montana. Mr. Holmes graduated from California State University at Long Beach with a degree in Biological Science.
Gregory Juda, Ph.D., is the Chief Scientific Officer for Bacterin International; a manufacturer of donor-derived specialty allografts and medical devices. Dr. Juda joined Bacterin International in 2005 and has played an integral role in the growth of Bacterin’s orthobiologics business. During his time with the company, Dr. Juda has been responsible for guiding the development, commercialization, and marketing of three revolutionary, life-enhancing allograft products: Bacterin's OsteoSponge® allograft family, OsteoSelect® Demineralized Bone Matrix Putty, and hMatrix® Acellular Dermal Matrix.
Dr. Juda is an expert in the design, manufacturing, regulation, and marketing of biologics and biologic-based medical devices. He was responsible for directing equipment, facility, and process validation efforts for Bacterin’s state-of-the-art allograft tissue processing facility. These efforts included the design and validation of programs for tissue processing and decontamination, facility cleaning and monitoring, and sterilization of finished product. Currently, Dr. Juda directs research and development efforts for Bacterin and serves as the primary source of technical and regulatory expertise for Bacterin’s sales and marketing initiatives. Dr. Juda received a Bachelor of Science in Biochemistry from Virginia Polytechnic Institute and State University and a Doctorate of Philosophy in Biochemistry from Montana State University—Bozeman. Dr. Juda’s current research interests include the processing and application of extracellular matrix bioscaffolds for biologic repair and replacement.
Molly Mason serves as the Vice President of Marketing and National Accounts for Bacterin. She is responsible for developing and overseeing Bacterin’s integrated marketing campaigns, brand development, social media and mobile platforms, as well as messaging and communication regarding Bacterin's products and services. Ms. Mason also targets national corporate partnerships and agreements with healthcare systems, including relations with group purchasing organizations and hospital networks. Prior to joining Bacterin, Ms. Mason served as a Promotions Director and Service Manager for a small network of restaurants and offers over 14 years of experience in hospitality and customer service experience, with 11 of those years specifically serving marketing management positions. She graduated with honors and received degrees in Marketing and Entrepreneurship from Montana State University–Bozeman.
Melanie Head has over 20 years of experience in the medical device industry serving in various sales leadership positions. Prior to joining Bacterin, Ms. Head was the Vice President of Sales and Marketing for Lumenis, Inc., where she had responsibility for $85 million in revenue and 60 field personnel. Ms. Head has held many executive sales positions during her career, including positions as director for Medtronic Physio-Control, Draeger Medical, and Nihon Kohden. In addition, she has held national accounts roles, including government accounts. Ms. Head began her career in finance and is a CPA, with a BA in Accounting and Business Data Systems from University of Texas at San Antonio. Ms. Head is responsible for management of the sales operations for Bacterin, including implementation of strategic sales initiatives and expanding Bacterin’s market presence and existing training program.
Mr. Smith brings over 25 years of experience in senior regulatory and quality assurance positions in the medical device industry, including experience in tissue banking as well. His most recent position was Vice President of Regulatory Affairs and Quality Assurance for Sound Surgical Technologies LLC/Solta Medical. Prior to this position, Mr. Smith worked for AlloSource and Valleylab (Covidien). He has extensive knowledge pertaining to ISO 13485, FDA, and AATB regulatory requirements, guidelines, and standards. As Vice President of Regulatory and Quality Assurance for Bacterin, he oversees Bacterin’s Regulatory and Quality department and Bacterin’s Quality System.
Mr. Bornheimer has over 25 years of experience in various senior level financial and business development roles with companies in the medical device industry. Prior to his appointment at Bacterin, he was Chief Financial Officer of Sound Surgical Technologies LLC which was acquired by Solta Medical Inc. in February of last year. Prior to that, he held a number of financial positions during his fifteen years with Pfizer Inc. in its Hospital Product Group Division. As Vice President of Finance, Mr. Bornheimer reports to John Gandolfo, the Company's Chief Financial Officer, and has responsibility over the day-to-day financial activities for Bacterin as well as internal and SEC reporting.